Use of economic evaluation in decision making: Evidence and recommendations for improvement

Drugs

Volumn 70, Issue 15, 2010, Pages 1917-1926

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cost analysis; Cost effectiveness; Economic implications; Healthcare expenditure; Modelling; Quality adjusted life years; Quality of life rating scales; Resource use

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG INDUSTRY; ECONOMIC EVALUATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; MONEY; NOTE; REIMBURSEMENT;

DECISION MAKING; EVALUATION STUDIES AS TOPIC; HEALTH POLICY; PHARMACEUTICAL PREPARATIONS;

EID: 77957695472     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11538120-000000000-00000     Document Type: Note

References (56)

1. Grootendorst P, Pierard E, Shim M. Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. Expert Rev Pharmacoecon Outcomes Res 2009; 9 (4): 353-364
2. Perleth M, Jakubowski E, Busse R. What is best practice in health care? State of the art and perspectives in improving the effectiveness and efficiency of the European health care systems. Health Pol 2001 Jun; 56 (3): 235-250
3. Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
4. Drummond M, Brown R, Fendrick AM, et al. Use of pharmacoeconomics information: report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 2003 Jul; 6 (4): 407-416
5. Centre for the Evaluation of Value and Risk in Health. The Tufts Cost-Effectiveness Analysis Registry [online]. Available from URL: https://research.tufts-nemc.org/cear/default. aspx [Accessed 2010 Apr 16]
6. McMaster University. Health Economic Evaluations Database [online]. Available from URL: http://library.mcmaster. ca/articles/health-economic- evaluations-database [Accessed 2010 Apr 16]
7. Centre for Reviews and Dissemination. National Health Service Economic Evaluation Database [online]. Available from URL: http://www.york.ac.uk/inst/ crd/ [Accessed 2010 Apr 16]
8. Pharmaceutical Benefits Advisory Committee [online]. Available from URL: http://www.health.gov.au/internet/ main/publishing.nsf/Content/ Pharmaceutical+Benefits+Ad visory+Committee-1 [Accessed 2010 Jul 27]
9. Medicine Reimbursement Committee [online]. Available from URL: http://www.riziv.fgov.be/drug/nl/drugs/decisions- report/report-crm-cgt/index. htm [Accessed 2010 Jul 27]
10. National Institute for Health and Clinical Excellence [online]. Available from URL: http://www.nice.org.uk [Accessed 2010 Jul 27]
11. High Health Authority [online]. Available from URL: http://www.has-sante. fr/portail/jcms/j-5/accueil [Accessed 2010 Jul 27]
12. Institute for Quality and Efficiency in Health Care [online]. Available from URL: http://www.iqwig.de [Accessed 2010 Jul 27]
13. Health Care Insurance Board [online]. Available from URL: http://www.cvz.nl [Accessed 2010 Jul 27]
14. Pharmaceutical Management Agency [online]. Available from URL: http://www.pharmac.govt.nz [Accessed 2010 Jul 27]
15. Scottish Medicines Consortium [online]. Available from URL: http://www.scottishmedicines.org.uk/smc/CCC-First Page.jsp [Accessed 2010 Jul 27]
16. Dental and Pharmaceutical Benefits Agency [online]. Available from URL: http://www.tlv.se/in-english [Accessed 2010 Jul 27]
17. Center for Drug Evaluation, Taiwan [online]. Available from URL: http://www.cde.org.tw/eng/default.html [Accessed 2010 Jul 27]
18. Simoens S. Health economic assessment: a methodological primer. Int J Environ Res PublicHealth 2009; 6 (12): 2950-2966
19. National Centre for Pharmacoeconomics.A review of the cost effectiveness of sunitinib (Sutent) under theHighTechDrug Scheme in Ireland [online]. Available from URL: http:// www.ncpe.ie/u-docs/doc-129.pdf [Accessed 2010 Jul 27]
20. Weinstein MC, Zeckhauser R. Critical ratios and efficient allocation. J Public Econ 1973; 2: 147-157
21. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001; 19: 1103-1109
22. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473-481
23. Raftery J. Review of NICEs recommendations, 1999-2005. BMJ 2006; 332: 1266-1268
24. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329: 224-227
25. Health Care Insurance Board. Richtlijnen voor farmacoeconomisch onderzoek [guidelines for pharmaco-economic research]. Amstelveen: Health Care Insurance Board, 1999
26. Webb D. Early assessment of cost-effectiveness. Congress of the European Association for Clinical Pharmacology and Therapeutics; 2009 Jul 12-15; Edinburgh
27. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50 000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008; 8: 165-178
28. National Institute for Health and Clinical Excellence. The guidelines manual 2009. London: National Institute for Health and Clinical Excellence [online]. Available from URL: http://www.nice.org.uk/aboutnice/howwework/de velopingniceclinicalguidelines/clinicalguidelinedevelopment methods/ GuidelinesManual2009.jsp [Accessed 2010 Jul 28]
29. Cleemput I, Neyt M, Thiry N, et al. Thresholds for costeffectiveness in health care. Brussels: Belgian Health Care Knowledge Centre, 2008
30. Simoens S. How to assess the value of medicines? Frontiers Pharmacoeconomics Health Outcomes. In press
31. Drummond M, Evans B, LeLorier J, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases. A case study in oncology. Can J Clin Pharmacol 2009; 16 (2): e273-81
32. Simoens S. Health economics of market access for biopharmaceuticals and biosimilars. JMed Econ 2009 Sep; 12 (3): 211-218
33. Simoens S, Laekeman G. Applying health technology assessment to pharmaceutical care: pitfalls and future directions. Pharm World Sci 2005 Apr; 27 (2): 73-75
34. Galani C, Rutten FF. Self-reported healthcare decisionmakers attitudes towards economic evaluations of medical technologies. Curr Med Res Opin. Epub 2008 Sep 29
35. Traulsen JM, Klinke BO. Using health technology assessment to put pharmaceutical care on the political agenda. Pharm World Sci 2004 Apr; 26 (2): 61-63
36. Hoffmann C, Graf von der Schulenburg JM. The influence of economic evaluation studies on decision making: a European survey. The EUROMET Group. Health Pol 2000 Jul; 52 (3): 179-192
37. Neumann PJ, Fang C, Cohen J. 30 years of pharmaceutical cost-utility analyses: growth, diversity, and methodological improvement. Pharmacoeconomics 2009; 27 (10): 861-872
38. Neumann PJ, Greenberg D, Olchanski NV, et al. Growth and quality of the cost-utility literature, 1976-2001. Value Health 2005 Jan-Feb; 8 (1): 3-9
39. Eddama O, Coast J. A systematic review of the use of economic evaluation in local decision-making. Health Pol 2008 May; 86 (2-3): 129-141
40. Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force Report. Value Health 2009 Jun; 12 (4): 409-418
41. Stoykova B, Drummond M, Barbieri M, et al. The lag between effectiveness and cost-effectiveness evidence of new drugs: implications for decision-making in health care. Eur J Health Econ 2003 Nov; 4 (4): 313-318
42. Tilson L, BarryM. Recent developments in Pharmacoeconomic evaluation in Ireland. Expert Rev Pharmacoecon Outcomes Res 2010; 10 (3): 221-224
43. Vinck I, Neyt M, Thiry N, et al. A procedure for the assessment of new medical devices. KCE reports 44A ed. Brussels: Belgian Health Care Knowledge Centre, 2006
44. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicares coverage with evidence development. Health Aff 2006; 25: 1218-1230
45. Cook JP, Vernon JA, Manning R. Pharmaceutical risksharing agreements. Pharmacoeconomics 2008; 26: 551-556
46. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006 Mar; 332 (7543): 699-703
47. Miners AH, Garau M, Fidan D, et al. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. BMJ 2005 Jan; 330 (7482): 65
48. Cleemput I, Van WP, Vrijens F, et al. Guidelines for pharmaco- economic evaluation in Belgium. Brussels: Belgian Health Care Knowledge Centre, 2008
49. GRADE Working Group [online]. Available from URL: http://www. gradeworkinggroup.org/ [Accessed 2010 Jul 27]
50. SIGN [online]. Available from URL: http://www.sign.ac. uk/ [Accessed 2010 Jul 27]
51. Thurston SJ, Craig D, Wilson P, et al. Increasing decisionmakers access to economic evaluations: alternative methods of communicating the information. Int J Technol Assess Health Care 2008; 24 (2): 151-157
52. Innvaer S, Vist G, Trommald M, et al. Health policy-makers perceptions of their use of evidence: a systematic review. J Health Serv Res Policy 2002 Oct; 7 (4): 239-244
53. Drummond M, Jonsson B. Moving beyond the drug budget silo mentality in Europe. Value Health 2003 Jul; 6 Suppl. 1: S74-7
54. Mitton CR, Donaldson C. Setting priorities and allocating resources in health regions: lessons from a project evaluating program budgeting and marginal analysis (PBMA). Health Policy 2003; 64: 335-348
55. Wettermark B, Godman B, Andersson K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008; 26 (7): 537-550
56. Williams I, McIver S, Moore D, et al. The use of economic evaluations in NHS decision-making: a review and empirical investigation. Health Technol Assess 2008 Apr; 12 (7): iii, ix-x, 1-175